The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Aveo; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Helsinn Therapeutics; Merck Serono; Pfizer
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Piotr Tomczak
No Relationships to Disclose
 
Jameel Muzaffar
No Relationships to Disclose
 
Ira Seth Winer
Research Funding - Oncoceutics
 
Seth David Rosen
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Pfizer
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); crispr therapeutics (Inst); Dynavax Technologies (Inst); Janssen Oncology (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); NanoCarrier (Inst); Nektar (Inst); NeoImmuneTech (Inst); Novartis (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Aman Chauhan
Honoraria - Ipsen; Lexicon; Novartis; TerSera
Consulting or Advisory Role - Ipsen; Lexicon; Novartis; TerSera
Research Funding - Bristol-Myers Squibb; Clovis Oncology; ECS Progastrin; TerSera
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Medison & Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Medison & Immunocore; Merck; Novartis; Oncorus
Research Funding - Alkermes; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen; Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; nektar; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Debora S. Bruno
Honoraria - Bristol Myers; Daiichi Sankyo/Astra Zeneca; Lilly; Mirati Therapeutics; Novartis; Tempus
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Mirati Therapeutics; Novartis; Tempus
Research Funding - AstraZeneca
 
Olivier Dumas
No Relationships to Disclose
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
James Fredric Strauss
Leadership - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Merck; Regeneron
Consulting or Advisory Role - Binhui Biopharmaceuticals, Ltd. (Inst); Synlogic (Inst)
 
Quincy S. Chu
Honoraria - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Esperas Pharma; Johnson & Johnson/Janssen; Lilly; Merck; Novartis; Ocellaris Pharma; Pfizer; Roche; Takeda
Research Funding - AstraZeneca
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Arvind Chaudhry
Stock and Other Ownership Interests - Novartis
Speakers' Bureau - Pharmacyclics
 
Julie R. Graham
Employment - Alkermes
Stock and Other Ownership Interests - Alkermes
 
Valentina Boni
Employment - Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Honoraria - Amunix; Guidepoint Global; IDEAYA Biosciences; Loxo; Puma Biotechnology
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Lilly; Solti; Tactics
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/Merck (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Marc S. Ernstoff
Stock and Other Ownership Interests - Bristol-Myers Squibb; GE Healthcare
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Foundation Medicine; GlaxoSmithKline; Lilly; Merck; Novartis
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)